Co-Diagnostics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
80.1%projected annual EPS growth
FY EPS (est.)
-$13.50next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Quarterly150K
Cash and Cash Equivalents Quarterly8.2MTarget: Sustain operational runway through commercialization
Watch Items
- FDA 510(k) clearance for the Co-Dx PCR Pro instrument and COVID-19 testTrigger: FDA clearance or request for additional clinical dataAction: Re-evaluate commercialization timeline and adjust R&D spending
- Commercialization progress of the Co-Dx PCR platform in India via CoSara joint ventureTrigger: Initial commercial sales volume of CoSara PCR Pro instrumentAction: Assess international revenue contribution and scale manufacturing
Research as of 20 Jun 2026